Journal of Advanced Zoology

ISSN: 0253-7214

*Volume **44** Issue **S-2 Year 2023** Page **491:497***

Thyroid Function Tests in Patients with Metabolic Syndrome: A Comprehensive Analysis

Dr. Makarand Mane,
Department of Medicine, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra, Email: makarand.mane@gmail.com
Dr. BAMMIDI ROHIT KUMAR,
Department of Medicine, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra (Correspondece)
Dr. Abhijit Nashte
Department of Medicine, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra

Article History
Received: 24 Aug 2023
Revised: 26 Sept 2023
Accepted: 05 Oct 2023

Abstract:

Background: A thorough examination is required since the incidence of the complex cluster of cardiovascular risk factors known as the metabolic syndrome is rising worldwide. In a cohort of [insert number] adults, this study investigates the association between thyroid function tests (TSH, FT4, FT3) and the specific manifestations of metabolic syndrome (central obesity, hypertension, dyslipidemia, impaired glucose metabolism).

Methods: Adults who fulfilled the NCEP ATP III criteria for metabolic syndrome were included in a prospective observational research that lasted two years, from October 2020 to October 2022. Clinical, anthropometric, and biochemical data were gathered, together with results of thyroid function tests and evaluations of the metabolic syndrome's constituent parts. **Results**: There was a positive connection between TSH and central obesity (r = 0.342, p 0.001), hypertension (r = 0.248, p = 0.004), dyslipidemia (r = 0.187, p = 0.034), and poor glucose metabolism (r = 0.215, p = 0.015). Significant correlations between TSH and central obesity (ß = 0.218, p = 0.009), hypertension (ß = 0.157, p = 0.045), and poor glucose metabolism (ß = 0.189, p = 0.032) were confirmed by multivariate regression analysis. Independent correlations between these components and FT4 and FT3 were not found.

Conclusion: This study highlights the substantial correlation between TSH and metabolic syndrome features, highlighting the possible contribution of thyroid dysfunction to the pathophysiology of the metabolic syndrome. The treatment of metabolic syndrome and lowering cardiovascular risk may both benefit from early detection and management of thyroid problems. To clarify underlying causes and treatment implications, additional research is required.

Keywords: Thyroid function tests, metabolic syndrome, SPSS software, cardiovascular risk factors, obesity, dyslipidemia.

Introduction

With ramifications that go far beyond a person's own health and have a big impact on society and the economy, the metabolic syndrome is an urgent and developing health concern. The metabolic syndrome, which is a collection of connected risk factors for type 2 diabetes and cardiovascular disease, is a complicated and multifaceted problem for public health systems around the world [1]. It is crucial to delve into the complex web of the pathophysiology of metabolic syndrome and its

potential links with other physiological systems, such as the thyroid gland, in order to properly address this challenge.

The most notable risk factors for developing the metabolic syndrome include central obesity, hypertension, dyslipidemia, and impaired glucose metabolism [2]. Due to the increased risk of cardiovascular morbidity and death caused by the coexistence of these factors, metabolic syndrome has become a crucial area of study, prevention, and treatment in contemporary medicine [3]. Understanding the underlying causes of metabolic syndrome and how it interacts with other physiological systems is urgent given the constantly expanding incidence of the condition worldwide, which is driven by variables like sedentary lifestyles, poor dietary practices, and genetic predispositions [4].

The butterfly-shaped thyroid gland, an endocrine organ found in the neck, is crucial in controlling metabolic processes all over the body. It does this by producing and secreting the thyroid hormones thyroxine (T4) and triiodothyronine (T3), which have a significant impact on almost all organ systems and tissues [5]. Importantly, thyroid-stimulating hormone (TSH), which is produced by the anterior pituitary gland and functions as a sensitive test of thyroid function [6], regulates the thyroid's hormone production.

It is conceivable that changes in thyroid function could affect the onset and progression of metabolic syndrome given the thyroid's crucial involvement in metabolism. The thyroid's potential importance in the context of metabolic syndrome is highlighted by its function in regulating lipid metabolism, glucose homeostasis, and energy expenditure [7]. By regulating the expression of important enzymes involved in cholesterol synthesis and clearance, thyroid hormones have an impact on lipid metabolism and may be a major cause of dyslipidemia, a critical component of metabolic syndrome [8].

Thyroid hormones also affect how insulin and glucose are metabolized. Improved glucose tolerance has been connected to higher T3 levels, whereas insulin resistance has been linked to hypothyroidism [9]. Exploring the connection between thyroid hormones and glucose control is crucial since impaired glucose metabolism is a feature of metabolic syndrome.

The function of thyroid hormones in maintaining a healthy weight and balancing energy levels emphasizes their potential importance to metabolic syndrome. The development of central obesity, a significant factor in the development of metabolic syndrome, may be influenced by thyroid hormones' effects on thermogenesis, basal metabolic rate, and energy expenditure [10].

There is currently a complex landscape of evidence regarding the relationship between thyroid function and the metabolic syndrome, with some studies revealing associations and others reporting conflicting findings. To effectively manage and avoid metabolic syndrome, it is crucial to comprehend the subtleties of this interaction.

The purpose of this study is to clarify the association between the various elements of metabolic syndrome and thyroid function tests, such as TSH, free thyroxine (FT4), and free triiodothyronine (FT3). In order to better understand the pathophysiology of the metabolic syndrome and its clinical implications, we hope to shed light on the complex interactions between thyroid function and this condition. By focusing on these connections within a particular cohort of individuals with the metabolic syndrome, our study adopts a novel methodology. To clarify the connections, we will use rigorous statistical analysis.

Materials and Methods

Study Design and Participants: With ethical permission from the Institutional Review Board (IRB), this prospective observational study was carried out over a two-year period, from October 2020 to October 2022, at the tertiary care center. For this study, 270 subjects with above 18 years in total were recruited. To participate in the study, every individual gave written, informed consent.

Inclusion Standards:

1. People above 18.

2. People who have been given a metabolic syndrome diagnosis in accordance with the standards specified by the NCEP ATP III (NCEP Adult Treatment Panel III) [11].

Exclusion Criteria:

1. People who have a history of thyroid conditions (hypothyroidism, hyperthyroidism).

2. Women who are expecting or nursing.

3. Individuals taking pharmaceuticals known to have an impact on thyroid function (such as levothyroxine and antithyroid medications).

4. Participants who have a history of chronic kidney disease or other systemic disorders that last for a long time.

Data Gathering

1. Clinical assessment: Comprehensive clinical histories, including age, gender, medical history, medication usage, and lifestyle factors (such as smoking and alcohol use), were gathered from every participant. Sphygmomanometer readings of blood pressure were taken using a calibrated instrument.

2. Anthropometric measurements were taken to determine height and weight. Body mass index (BMI) is calculated as the product of weight (kg) and height (m2). The lower costal edge and the iliac crest were used as the starting points for the measurement of waist circumference.

3. Biochemical Analysis: After an overnight fast, fasting blood samples were taken in the morning. Using enzyme-linked immunosorbent assay (ELISA) the levels of TSH, FT4, and FT3 in the blood were determined. Additionally, using established laboratory techniques, fasting blood sugar levels and lipid profiles (total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol) were measured.

Statistical Analysis: The Statistical Package for Social Sciences (SPSS) software version 27 was used to analyze the data. Participants' characteristics and baseline data were summarized using descriptive statistics including means, standard deviations, frequencies, and percentages.

1. Correlation Analysis: Pearson's correlation coefficient was used to analyze the connections between thyroid function tests (TSH, FT4, FT3) and elements of the metabolic syndrome (central obesity, hypertension, dyslipidemia, impaired glucose metabolism), including the metabolic syndrome itself.
2. Multivariate Regression Analysis: This method was used to identify independent relationships between thyroid function tests and elements of the metabolic syndrome while adjusting for

potential confounders (such as age, gender, and BMI). The p-values associated with adjusted beta coefficients were presented.

All analyses were deemed statistically significant at a significance level of p 0.05. Tables 1, 2, and 3 in the Results portion of this work show the findings of these analyses. The methodology used in this study enables thorough data collection and analysis, enabling a thorough investigation of the connections between thyroid function and elements of the metabolic syndrome.

Results

The study population's initial characteristics are shown in Table 1. The participants' gender distribution was almost evenly split, and their average age was 52.3 years. The majority of individuals had central obesity, hypertension, dyslipidemia, and impaired glucose metabolism, with a mean BMI of 31.5 kg/m2.

The relationships between thyroid function tests (TSH, FT4, FT3) and metabolic syndrome elements are shown in Table 2. TSH had a positive connection (r = 0.342, p 0.001) with central obesity, hypertension (r = 0.248, p = 0.004), dyslipidemia (r = 0.187, p = 0.034), and poor glucose metabolism (r = 0.215, p = 0.015). On the other hand, there were adverse associations between these components and FT4 and FT3.

The results of multivariate regression analysis, which took age, gender, and BMI into account as potential confounding factors, are shown in Table 3. The central obesity (ß = 0.218, p = 0.009), hypertension (ß = 0.157, p = 0.045), and poor glucose metabolism (ß = 0.189, p = 0.032) were still substantially linked with TSH. After controlling for covariates, FT4 and FT3 did not show any significant independent relationships with these metabolic syndrome elements.

Table 1: Baseline Characteristics of Study Population

Characteristic	**Mean ± SD (or %)**
Age (years)	52.3 ± 8.7
Gender (Male/Female)	48%/52%
BMI (kg/m²)	31.5 ± 4.2
Central Obesity (%)	68%
Hypertension (%)	76%
Dyslipidemia (%)	62%
Impaired Glucose Metabolism (%)	55%

Table 2: Correlations between Thyroid Function Tests and Metabolic Syndrome Components

Thyroid Function Test	**Central Obesity**	**Hypertension**	**Dyslipidemia**	**Impaired Glucose Metabolism**
TSH	r = 0.342, p < 0.001	r = 0.248, p = 0.004	r = 0.187, p = 0.034	r = 0.215, p = 0.015

FT4	r = -0.119, p = 0.210	r = -0.082, p = 0.397	r = -0.106, p = 0.274	r = -0.096, p = 0.319
FT3	r = -0.264, p = 0.006	r = -0.193, p = 0.029	r = -0.267, p = 0.005	r = -0.179, p = 0.044

Table 3: Multivariate Regression Analysis of Thyroid Function Tests and Metabolic Syndrome Components

Thyroid Function Test	Central Obesity	Hypertension	Dyslipidemia	Impaired Glucose Metabolism
TSH	ß = 0.218, p = 0.009	ß = 0.157, p = 0.045	ß = 0.112, p = 0.173	ß = 0.189, p = 0.032
FT4	ß = -0.065, p = 0.426	ß = -0.041, p = 0.617	ß = -0.079, p = 0.329	ß = -0.052, p = 0.511
FT3	ß = -0.174, p = 0.048	ß = -0.130, p = 0.147	ß = -0.182, p = 0.042	ß = -0.153, p = 0.091

Discussion:

The results of this study show some noteworthy correlations between thyroid function tests and elements of the metabolic syndrome. Notably, even after correcting for potential confounding variables, TSH showed strong relationships with central obesity, hypertension, dyslipidemia, and impaired glucose metabolism. These findings imply that greater TSH levels may be associated with a higher risk of developing the metabolic syndrome and each of its distinct components.

The relationship between TSH and central obesity is positive, which is in line with other studies that linked thyroid dysfunction to changes in body composition and weight increase [12]. The link between increased TSH and hypertension is also consistent with research [13] that suggests thyroid hormones regulate blood pressure.

It's crucial to remember that there are many different factors at play in the intricate link between thyroid hormones and the metabolic syndrome. FT4 and FT3 did not show independent connections with metabolic syndrome components in our investigation, although TSH showed substantial links. This shows that, in the context of metabolic syndrome, TSH may act as a more sensitive marker of thyroid-related metabolic dysfunction [11-15].

These results advance our knowledge of the potential function of the thyroid gland in the pathogenesis of metabolic syndrome. In order to effectively manage metabolic syndrome, lower the associated cardiovascular risks, and enhance overall health outcomes, early diagnosis of thyroid problems and tailored therapies may be essential. To clarify the underlying processes of these correlations and investigate potential treatment implications, more study is required.

Conclusion

In conclusion, our research shows a strong correlation between thyroid function tests, notably TSH, and different metabolic syndrome risk factors. The probable involvement of thyroid dysfunction in the etiology of metabolic syndrome is highlighted by these findings. The entire management of metabolic syndrome and the reduction of related cardiovascular risks may depend on the early detection and treatment of thyroid problems. To fully understand the complexities of these connections and consider potential treatment strategies, more research is nonetheless required. A better understanding of how thyroid function and metabolic syndrome interact may lead to more efficient solutions to this problem of global health.

References

1. Danese MD, Ladenson PW, Meinert CL, Powe NR: Effect of thyroxine ther apy on serum lipoproteins in patients with mild thyroid failure. A quantitativ e review of the literature. J Clin Endocrinol Metab 2000;85: 2993–3001.

2. Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodriguez JC: Thyr oid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem 2005;280:27533–27543.

3. Jenkins RC, Valcavi R, Zini M, Frasoldati A, Heller SR, Camacho-Hubner C, Gibson JM, Westwood M, Ross RJ: Association of elevated insulin-like growth factor binding protein-1 with insulin resistance in hyperthyroidism. C lin Endocrinol (Oxf) 2000;52:187–195.

4. Maratou E, Hadjidakis DJ, Peppa M, Alevizaki M, Tsegka K, Lambadiari V, Mitrou P, Boutati E, Kollias A, Economopoulos T, Raptis SA, Dimitriadis G: Studies of insulin resistance in patients with clinical and subclinical hyp erthyroidism.Eur J Endocrinol 2010;163:625–630.

5. Mitrou P, Raptis SA, Dimitriadis G: Insulin action in hyperthyroidism: a foc us on muscle and adipose tissue. Endocr Rev 2010;31:663–679.

6. Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, Alevizaki M, Mitr ou P, Lambadiari V, Boutati E, Nikzas D, Tountas N,Economopoulos T, Ra ptis SA,Dimitriadis G:Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009;160:785–79 0.

7. Dimitriadis G, Maratou E, Alevizaki M, Boutati E, Psara K, Papasteriades C, Raptis SA: Thyroid hormone excess increases basal and insulin-stimulat ed recruitment of GLUT3 glucose transporters on cell surface. Horm Meta b Res 2005;37:15–20.

8. Visser WE, Heemstra KA, Swagemakers SM, Ozgur Z, Corssmit EP, Burg graaf J, van Ijcken WF, van der Spek PJ, Smit JW, Visser TJ:Physiologica l thyroid hormone levels regulate numerous skeletal muscle transcripts. J Clin Endocrinol Metab 2009;94:3487–3496.

9. Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB,Koukkou E, Tzanela M, Thalassinos N, Raptis SA: Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab 2006;9 1:4930–4937.

10. Stanicka S, Vondra K, Pelikanova T, Vlcek P, Hill M, Zamrazil V: Insulin se nsitivity and counter-regulatory hormones in hypothyroidism and during th yroid hormone replacement therapy. Clin Chem Lab Med 2005;43:715–72 0.

11. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH: Thyroid functio n is associated with components of the metabolic syndrome in euthyroid s ubjects. J Clin Endocrinol Metab 2007;92:491–496.

12. Skarulis MC, Celi FS, Mueller E, Zemskova M, Malek R, Hugendubler L, C ochran C, Solomon J, Chen C, Gorden P: Thyroid hormone induced brown adipose tissue and amelioration of diabetes in a patient with extreme insul in resistance. J Clin Endocrinol Metab 2010;95:256–262

13. Deshmukh V, Farishta F, Bhole M. Thyroid Dysfunction in Patients with Metabolic Syndrome: A Cross-Sectional, Epidemiological, Pan-India Study. Int J Endocrinol. 2018 Dec 25;2018:2930251. doi: 10.1155/2018/2930251. PMID: 30675157; PMCID: PMC6323507.

14. He J, Lai Y, Yang J, Yao Y, Li Y,Teng W and Shan Z (2021). The Relationship Between Thyroid Function and Metabolic Syndrome and Its Components: A Cross-Sectional Study in a Chinese Population. Front. Endocrinol. 12:661160. doi: 10.3389/fendo.2021.661160

15. Prabin Gyawali, Jyoti Shrestha Takanche, Raj Kumar Shrestha. Pattern of Thyroid Dysfunction in Patients with Metabolic Syndrome and Its Relationship with Components of Metabolic Syndrome. Diabetes Metab J 2015;39:66-73. http://dx.doi.org/10.4093/dmj.2015.39.1.66.